Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2029

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Resection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System

The Elekta Xoft® Axxent® Electronic Brachytherapy (eBx®) System is a device that delivers high-dose-rate radiation. It is designed for use with Axxent applicators to treat neoplastic tumors inside or on the body surface where radiation therapy is indicated. The Axxent System and its applicators were cleared by the FDA under 510(k) submissions K050843, K072683, K090914, and K122951. The Russian Federation medical device registration certificate (No. RZN 2015/2593) was obtained on April 17, 2015.

Trial Locations (1)

129090

RECRUITING

Joint-Stock Company European Medical Center, Moscow

All Listed Sponsors
lead

Joint Stock Company European Medical Centre

OTHER

NCT07141732 - Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy | Biotech Hunter | Biotech Hunter